Investigational drug · Phase 2
GFH276
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for RAS Mutation, Pancreatic Cancer, Non-small Cell Lung Cancer (NSCLC).
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
5
5 still active
All registered trials
5
Any phase or sponsor naming "GFH276"
First trial start
2025
Sep 18, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GFH276", any sponsor or status.
Conditions studied
As listed on its trial records.
- RAS Mutation
- Pancreatic Cancer
- Non-small Cell Lung Cancer (NSCLC)
- Cancer
- PDAC
- CRC (Colorectal Cancer)
- NSCLC
- Advanced Solid Tumors Cancer
- Pancreatic Ductal Adenocarcinoma
- CRC
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Colorectal cancer · Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "GFH276" as an intervention, largest first.
Genfleet Therapeutics (Shanghai) Inc.Industry
NCT07198321 · 450 participants (planned) · Start Sep 18, 2025 · Primary completion Jul 30, 2027
Drug: GFH276 · For: Cancer; PDAC; CRC (Colorectal Cancer) and 1 more
Sites: Guangzhou, China
Genfleet Therapeutics (Shanghai) Inc.Industry
NCT07678593 · 222 participants (planned) · Start Sep 2026 · Primary completion Nov 2027
Drug: GFH276; Cetuximab and 6 more · For: Advanced Solid Tumors Cancer; Pancreatic Ductal Adenocarcinoma; RAS Mutation
Sites: Concord, Australia; North Ryde, Australia; Woodville South, Australia · 17 sites in all
- A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal CancerNot yet recruiting
Genfleet Therapeutics (Shanghai) Inc.Industry
NCT07915921 · 150 participants (planned) · Start Nov 15, 2026 · Primary completion Apr 30, 2028
Drug: Irinotecan; Oxaliplatin and 5 more · For: CRC
- A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D MutationPivotal-lookingRecruiting
Genfleet Therapeutics (Shanghai) Inc.Industry
NCT07784374 · 120 participants (planned) · Start Aug 20, 2026 · Primary completion Aug 31, 2028
Drug: GFH375; GFH276 and 1 more · For: Pancreatic Cancer
Sites: Shanghai, China
Genfleet Therapeutics (Shanghai) Inc.Industry
NCT07846358 · 84 participants (planned) · Start Nov 2026 · Primary completion Dec 2027
Drug: GFH276; with or without Tislelizumab and 3 more · For: RAS Mutation; Non-small Cell Lung Cancer (NSCLC)
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for RAS Mutation
- TNG462Phase 23 trials
Tango Therapeutics, Inc. · MTAP-deleted Solid Tumors, Locally Advanced Solid Tumor, PDAC
- ERAS-0015Phase 21 trial
Tango Therapeutics, Inc. · PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC
- OKI-179Phase 21 trial
OnKure, Inc. · RAS Mutation, NRAS Gene Mutation, Melanoma
- vopimetostatPhase 21 trial
Tango Therapeutics, Inc. · PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.